title: Loss to care and death before antiretroviral therapy in Durban, South Africa.
abstract: OBJECTIVE
  To examine the loss to care and mortality rates before starting antiretroviral therapy (ART) among ART eligible HIV-infected patients in Durban, South Africa.
  
  
  METHODS
  Retrospective cohort study.
  
  
  METHODS
  We reviewed data from ART eligible adults (> or = 18 years) at an urban HIV clinic that charges a monthly fee from July to December 2006. ART eligibility was based on CD4 count < or = 200 cells per microliter or clinical criteria and a psychosocial assessment. Patients who did not start ART and were lost within 3 months were phoned. Correlates of loss to care were evaluated using logistic regression.
  
  
  RESULTS
  During the study period, 501 patients registered for ART training. Mean time from initial CD4 count to first ART training was 3.6 months (interquartile range 2.3-3.9 months). Four hundred eight patients (81.4%) were in care and on ART at 3-month follow-up, and 11 (2.2%) were in care but had not initiated ART. Eighty-two ART eligible patients (16.4%) were lost before ART initiation. Of these, 28 (34.1%) had died; two thirds of deaths occurred before or within 2 months after the first ART training. Despite multiple attempts, 32 patients (39%) were unreachable by phone. Lower baseline CD4 counts (< or = 100 cells/microL) and unemployment were independently associated with being lost.
  
  
  CONCLUSIONS
  Loss to care and death occur frequently before starting ART at an HIV clinic in Durban, South Africa. This delay from CD4 count to ART training, even among those with the lowest CD4 counts, highlights the need for interventions that improve linkage to care and prioritize ART initiation for those with low baseline CD4 counts.
authors.affiliation: Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA 02114, USA. ibassett@partners.org
authors.forename: Ingrid V
authors.initials: IV
authors.lastname: Bassett
authors.forename: Bingxia
authors.initials: B
authors.lastname: Wang
authors.forename: Senica
authors.initials: S
authors.lastname: Chetty
authors.forename: Matilda
authors.initials: M
authors.lastname: Mazibuko
authors.forename: Benjamin
authors.initials: B
authors.lastname: Bearnot
authors.forename: Janet
authors.initials: J
authors.lastname: Giddy
authors.forename: Zhigang
authors.initials: Z
authors.lastname: Lu
authors.forename: Elena
authors.initials: E
authors.lastname: Losina
authors.forename: Rochelle P
authors.initials: RP
authors.lastname: Walensky
authors.forename: Kenneth A
authors.initials: KA
authors.lastname: Freedberg
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000627:therapeutic use*; D015331:Cohort Studies; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000401:mortality*; D006801:Humans; D008297:Male; D016017:Odds Ratio; D012189:Retrospective Studies; D013019:South Africa / Q000453:epidemiology
chemical_list: D019380:Anti-HIV Agents